Review Decision - February 2016
Review of NICE Technology Appraisal Guidance No. 112; Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer
Decision to update the technology appraisal in an ongoing clinical guideline – February 2016
The Institute was proposing that TA112 should be updated in a forthcoming clinical guideline.
After consideration of all of the comments received during the Review Consultation, the Technology Appraisals programme has decided to proceed with this proposal.
Consequently, TA112 will be updated in the forthcoming update of CG80 (Early and locally advanced breast cancer: diagnosis and treatment), which is due to be published in July 2018. Upon publication of this clinical guideline, the recommendations in TA112 will be superseded, and the guidance will be withdrawn.
This page was last updated: 22 February 2016